Skip to main content
SpringerLink
Log in

The potential role of lonidamine (LND) in the treatment of malignant glioma

Phase II study

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Up-to-date unsatisfactory results obtained in multimodality treatments of malignant glioma have prompted the research of new therapeutic modalities with ‘unconventional’ modes of action. Lonidamine (LND) is a drug which reduces aerobic glycolytic activity in both human and experimental tumors. This effect mainly depends on the inhibition of mitochondrially-bound hexokinase (HK) which is present in large amounts in malignant cells. A Phase II study was conducted on patients with recurrent glioma; 12 patients were admitted to the study. Clinical side effects were moderate, necessitating a reduction of the dosage in only 1 case. The objective results were evaluated according to the indications of Levin. 2 responders and 3 cases of stable disease were observed out of 10 evaluable patients. The potential value of this new drug is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Caputo A: Preliminary results in some tumor systems with indazole-carboxylic acids. Chemotherapy 27 (suppl. 2):107–120, 1981

    Google Scholar 

  2. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:477–479, 1981

    Google Scholar 

  3. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41:4661–4666, 1981

    Google Scholar 

  4. Di Chiro G, De La Paz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kufta CV, Kessler RM, Johnston GS, Manning RG, Wolf AP: Glucose utilization of cerebral gliomas measured by (18F) fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329, 1982

    Google Scholar 

  5. Kirsch WM, Tucker WS, Tabuchi K, Fink LM, Van Burskirk JJ, Low M: The metabolism of the glioblastoma: pathobiological correlates. Clin Neurosurg 25:310–325, 1978

    Google Scholar 

  6. Kornblith PL, Cummins CJ, Smith BH, Brooks RA, Patronas NJ, Di Chiro G: Correlation of experimental and clinical studies of metabolism by PET scanning. Prog Exp Tumor Res 27:170–178, 1984

    Google Scholar 

  7. Perria L, Viale GL, Ibba F, Andreussi L, Viale E: Istochimica dei tumori endocranici. Neuropsichiatria 20:419–523, 1964

    Google Scholar 

  8. Graham JF, Cummins JF, Smith BH, Kornblith PL: Regulation of hexokinase in cultured gliomas. Neurosurgery 17:537–542, 1985

    Google Scholar 

  9. Paggi MG, Carapella CM, Fanciulli M, Del Carlo C, Giorno S, Zupi G, Silvestrini B, Caputo A, Floridi A: Effect of lonidamine on human malignant gliomas: biochemical studies. J Neurooncol, In press

  10. Paggi MG, Zupi G, Fanciulli M, Del Carlo C, Giorno S, Laudonio N, Silvestrini B, Caputo A, Floridi A: Effect of Lonidamine on the utilization of 14C-labelled glucose by human astrocytoma cells. Exp and Mol Pat 47:154–165, 1987

    Google Scholar 

  11. Young CW, Currie VE, Kim JH, O'Heir MA, Farag FM, Kinahan JE: Phase I and clinical pharmacological evaluation of lonidamine in patients with advanced cancer. Oncology 41 (suppl. 1):60–65, 1984

    Google Scholar 

  12. Evans WK, Shepherd FA, Mullis B: Phase II evaluation of lonidamine in patients with advanced malignancy. Oncology 41 (suppl. 1):69–77, 1984

    Google Scholar 

  13. Band PR, Deschamps M, Besner JG, Leclaire R, Gervais P, De Sanctis A: Phase I toxicologic study of lonidamine in cancer patients. Oncology 41 (suppl. 1):56–59, 1984

    Google Scholar 

  14. Barduagni A, Barduagni M, Di Lauro L, Nardi M, Gallo Curcio C, Tonachella R, Ciottoli GB, Delle Chiaie S: Early observations on the administration of lonidamine in cancer patients. Oncology 41 (suppl. 1):78–81, 1984

    Google Scholar 

  15. Carapella CM, Iandolo B, Delle Chiaie S, Riccio A: Lonidamine in primary malignant brain tumors: preliminary report. Oncology 41 (suppl. 1):82–85, 1984

    Google Scholar 

  16. Kokron O, Maca S, Schemer W De Gregorio M, Ciottoli GB: Lonidamine in non small-cell lung cancer. Phase II study. Proc 14th Int Cancer Congr. 4853, 1986

  17. Weinerman B, Eisenhauer E, Maroun J, Coppin C, Armitage G: Phase II evaluation of lonidamine in advanced renal cell carcinoma. Proc ASCO, 156, 1984

  18. Band PR, Weinerman B, Eisenhauer E, Murray N: Lonidamine, a new anticancer agent: overview of canadian trials. Proc 14th Int Cancer Congr, 810, 1986

  19. Di Silverio F, Tenaglia R, Saragnano G, Ciottoli GB, De Gregorio M, Ferraro F: Lonidamine in carcinoma of the prostate. Rec Adv in Chemotherapy (Tokyo):616–618, 1985

  20. Zulch KJ: Types histologiques des tumeurs du système nerveux central. Classification histologique internationale des tumeurs. WHO, Genève, 1979

    Google Scholar 

  21. Miller AB, Hoostraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  22. Pouillart P, Palangie T, Poisson M, Buge A, Huguenin P, Morin P, Gautier H: Treatment of adult malignant gliomas. In: Recent results in cancer research. Springer. Berlin, 1979, pp 399–407

    Google Scholar 

  23. De Myer W: Tecnica dell'esame neurologico. Piccin. Padova, 1980, pp 357–360

    Google Scholar 

  24. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB: Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329–335, 1977

    Google Scholar 

  25. Chang CH, Horton J, Schoenfeld D, Salazar O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52:997–1007, 1983

    Google Scholar 

  26. Cianfriglia F, Pompili A, Riccio A, Grassi A: CCNU chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer 45:1289–1299, 1980

    Google Scholar 

  27. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr., Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr., Odom GL, Paoletti P, Ransohoff J, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr., Wilson CB, Strike TA: Comparison of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121–132, 1983

    Google Scholar 

  28. Poisson M, Pouillart P, Pertuiset BF: La chimiotherapie des glioblastomes. Encycl Med Chir, Paris. Neurologic 17305 B10, 6, 1982

    Google Scholar 

  29. Shapiro WR: Combined modality treatment of malignant glioma. Progr Exp Tumor Res 29:219–224, 1985

    Google Scholar 

  30. Walker MD, Alexander E, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343, 1978

    Google Scholar 

  31. Hahn GM, Van Kersen I, Silvestrini B: Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 50:657–660, 1984

    Google Scholar 

  32. Kim JH, Alfieri AA, Kim SH, Young CW: Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Res 46:1120–1123, 1986

    Google Scholar 

  33. Carapella CM, Paggi MG, Ciottoli GB, Cattani F, Floridi A, Fontana M, Jandolo B, Pompili A, Raus L, Riccio A, Caputo A: The potential role of lonidamine in the treatment of malignant glioma. Proc 14th Int Cancer Congr, 2944, 1986

  34. Gallo Curcio C, Salvati F, Rinaldi M, Venturo I, Tonachella R, Tropea F, Ambesi Impiombato F, Antilli A, Cruciani AR, De Gregorio M, Ciottoli GB: Chemo-radiotherapy ± lonidamine in non small cell lung cancer — limited disease. Preliminary results. Proc 14th Int Cancer Congr, 4856, 1986

  35. Magno L, Terraneo F, Scandolaro L, Bertoni F, De Gregorio M, Ciottoli GB: Lonidamine and radiotherapy in head and neck cancer. Preliminary report. Proc 14th Int Cancer Congr, 1769, 1986

Download references

Author information

Authors and Affiliations

  1. ‘Regina Elena’ Institute for Cancer Research, Rome, Italy

    Carmine M. Carapella, Marco G. Paggi, Fabio Cattani, Aristide Floridi, Bruno Iandolo, Laura Raus, Antonio Riccio & Antonio Caputo

  2. F. Angelini Research Institute, Rome, Italy

    Giovanni B. Ciottoli

Authors
  1. Carmine M. Carapella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco G. Paggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabio Cattani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanni B. Ciottoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aristide Floridi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruno Iandolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laura Raus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Riccio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio Caputo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carapella, C.M., Paggi, M.G., Cattani, F. et al. The potential role of lonidamine (LND) in the treatment of malignant glioma. J Neuro-Oncol 7, 103–108 (1989). https://doi.org/10.1007/BF00149384

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00149384

Key words

Search

Navigation